Company Description
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer.
The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.
It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers.
The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024.
Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
| Country | United States |
| Founded | 1998 |
| IPO Date | Jul 25, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Werner Cautreels |
Contact Details
Address: 12 Penns Trail Newtown, Pennsylvania 18940 United States | |
| Phone | 267 759 3680 |
| Website | trawspharma.com |
Stock Details
| Ticker Symbol | TRAW |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001130598 |
| ISIN Number | US68232V8019 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Werner Cautreels Ph.D. | Chief Executive Officer and Director |
| Mark Patrick Guerin CPA | Chief Financial Officer |
| Dr. Victor Moyo M.D. | Chief Medical Officer of Oncology |
| Dr. Iain D. Dukes DPHIL, M.A., Ph.D. | Executive Chairman |
| Dr. Nikolay Savchuk Ph.D. | Chief Operating Officer and Director |
| Dr. Robert R. Redfield M.D. | Chief Medical Officer |
| Dr. Charles David Pauza Ph.D. | Chief Scientific Officer of Virology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 6, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 1, 2024 | 8-K | Current Report |
| Oct 23, 2024 | ARS | Filing |
| Oct 11, 2024 | DEF 14A | Other definitive proxy statements |
| Sep 27, 2024 | 8-K | Current Report |
| Sep 23, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 17, 2024 | 8-K | Current Report |